Active substance
Progesterone
- SFDA 8
- US FDA 26
- Health Canada 12
- US price lines 9
- NHS prices 5
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CYCLOGEST 200MG PESSARIES | 200 mg | Pessary · Vaginal use | 15 Blister | SAR 66.20 | NCE · Prescription | L.D Collins & CO Ltd | Valid |
| CYCLOGEST 400MG PESSARIES | 400 mg | Pessary · Vaginal use | 15 Blister | SAR 87.65 | NCE · Prescription | L.D Collins & CO Ltd | Valid |
| Crinone | 8 % | Vaginal gel · Vaginal use | 15 Vaginal Sponge Applicator | SAR 185.05 | NCE · Prescription | MERCK SERONO EUROPE LTD | Valid |
| ENDOMETRIN 100 mg vafinal tablet | 100 mg | Vaginal tablet · Vaginal use | 21 Blister | SAR 84.20 | NCE · Prescription | FERRING | Valid |
| Lutigest | 200 mg | Capsule, soft · Oral use , Vaginal use | 15 Blister | SAR 59.50 | Generic · Prescription | Exeltis Healthcare S.L | Valid |
| PROLUTEX | 25 mg | Solution for injection · intramuscular, subcutaneous | 7 Vial | SAR 213.00 | NCE · Prescription | IBSA Istitut Biochimique SA | Valid |
| Utrogestan | 100 mg | Capsule, soft · Oral use , Vaginal use | 30 Blister | SAR 67.60 | Generic · Prescription | Laboratoires Besins International | Valid |
| Utrogestan | 200 mg | Capsule, soft · Oral use , Vaginal use | 15 Blister | SAR 67.60 | Generic · Prescription | Laboratoires Besins International | Valid |
Indications — CHI Daman Drug Formulary
MATERNAL AND CHILD HEALTHCARE- PREVENTION OF PRETERM LABOR AND BIRTH
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CRINONE | 8% | gel · vaginal | WATSON LABS INC | Prescription | 13 May 1997 |
| CRINONE | 8% | gel · vaginal | ABBVIE | Prescription | 31 Jul 1997 |
| PROMETRIUM | 100MG; 200MG | capsule · oral | ACERTIS PHARMS | Prescription | 14 May 1998 |
| PROMETRIUM | 100MG; 200MG; 300MG | capsule · oral | VIRTUS PHARMS | Prescription | 16 Dec 1998 |
| PROGESTERONE | 50MG/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 25 Apr 2001 |
| ENDOMETRIN | 100MG | insert · vaginal | FERRING | Prescription | 21 Jun 2007 |
| PROGESTERONE | 50MG/ML | injectable · injection | HIKMA FARMACEUTICA | Prescription | 28 Oct 2010 |
| PROGESTERONE | 100MG; 200MG | capsule · oral | SOFGEN PHARMS | Prescription | 28 Sep 2012 |
| PROGESTERONE | 100MG; 200MG | capsule · oral | BIONPHARMA | Prescription | 16 Aug 2013 |
| PROGESTERONE | 100MG; 200MG | capsule · oral | DR REDDYS | Prescription | 28 Feb 2017 |
| PROGESTERONE | 100MG; 200MG | capsule · oral | AMNEAL PHARMS NY | Prescription | 7 Sep 2017 |
| PROGESTERONE | 100MG; 200MG | capsule · oral | XIROMED | Prescription | 20 Oct 2017 |
| PROGESTERONE | 100MG; 200MG | capsule · oral | EUGIA PHARMA | Prescription | 26 Oct 2018 |
| PROGESTERONE | 50MG/ML | injectable · injection | EUGIA PHARMA | Prescription | 6 Dec 2018 |
| PROGESTERONE | 50MG/ML | injectable · injection | XIROMED | Prescription | 5 Jan 2022 |
| PROGESTERONE | 50MG/ML | injectable · injection | ACCORD HLTHCARE | Prescription | 21 Nov 2023 |
| PROGESTERONE | 100MG | insert · vaginal | XIROMED | Prescription | 19 Sep 2025 |
| PROGESTERONE | 100MG | insert · vaginal | GLENMARK PHARMS | Prescription | 8 Apr 2026 |
| PROGESTERONE | 50MG/ML; 25MG/ML | injectable · injection | LILLY | Discontinued | 1 Nov 1974 |
| PROGESTASERT | 38MG | insert, extended release · intrauterine | ALZA | Discontinued | 4 Feb 1976 |
| PROGESTERONE | 50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | ACTAVIS LABS UT INC | Discontinued | 11 May 1978 |
| CRINONE | 4% | gel · vaginal | ABBVIE | Discontinued | 31 Jul 1997 |
| PROMETRIUM | 300MG | capsule · oral | ACERTIS PHARMS | Discontinued | 14 May 1998 |
| PROGESTERONE | 50MG/ML | injectable · injection | AM REGENT | Discontinued | 22 Jun 2009 |
| PROGESTERONE | 100MG; 200MG | capsule · oral | TEVA PHARMS | Discontinued | 29 Feb 2012 |
1 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACH-PROGESTERONE | 02549158 | 100 MG | CAPSULE · ORAL | ACCORD HEALTHCARE INC |
| ACT PROGESTERONE INJECTION | 02446820 | 50 MG / ML | SOLUTION · INTRAMUSCULAR | TEVA CANADA LIMITED |
| AURO-PROGESTERONE | 02493578 | 100 MG | CAPSULE · ORAL | AURO PHARMA INC |
| CRINONE | 02241013 | 8 % | GEL · VAGINAL | EMD SERONO, A DIVISION OF EMD INC., CANADA |
| ENDOMETRIN | 02334992 | 100 MG | VAGINAL TABLET (EFFERVESCENT) · VAGINAL | FERRING INC |
| M-PROGESTERONE | 02551268 | 100 MG | CAPSULE · ORAL | MANTRA PHARMA INC |
| PMS-PROGESTERONE | 02476576 | 100 MG | CAPSULE · ORAL | PHARMASCIENCE INC |
| PROGESTERONE | 02516187 | 100 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| PROGESTERONE INJECTION, USP | 02531828 | 50 MG / ML | SOLUTION · INTRAMUSCULAR | HIKMA CANADA LIMITED |
| PROMETRIUM | 02166704 | 100 MG | CAPSULE · ORAL | ORGANON CANADA INC. |
| REDDY-PROGESTERONE | 02463113 | 100 MG | CAPSULE · ORAL | DR. REDDY'S LABORATORIES INC |
| TEVA-PROGESTERONE | 02439913 | 100 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CRINONE 4% GEL | $16.84389 | per GM | 2 Jan 2026 |
| US NADAC | CRINONE 8% GEL | $27.97261 | per GM | 23 Sep 2026 |
| US NADAC | ENDOMETRIN 100 MG VAG INSERT | $15.15184 | per EA | 23 Sep 2026 |
| US NADAC | PROGESTERONE 100 MG CAPSULE | $0.22903 | per EA | 23 Sep 2026 |
| US NADAC | PROGESTERONE 100 MG VAG INSERT | $10.87559 | per EA | 23 Sep 2026 |
| US NADAC | PROGESTERONE 200 MG CAPSULE | $0.40405 | per EA | 23 Sep 2026 |
| US NADAC | PROGESTERONE 500 MG/10 ML VIAL | $1.36055 | per ML | 23 Sep 2026 |
| US NADAC | PROMETRIUM 100 MG CAPSULE | $15.90949 | per EA | 23 Sep 2026 |
| US NADAC | PROMETRIUM 200 MG CAPSULE | $30.39475 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Progesterone 100mg pessaries | £19.50 | 21 pessary | 1 Oct 2026 |
| NHS Drug Tariff | Progesterone 200mg pessaries | £8.95 | 15 pessary | 1 Oct 2026 |
| NHS Drug Tariff | Progesterone 25mg/1.112ml solution for injection vials | £56.00 | 7 vial | 1 Oct 2026 |
| NHS Drug Tariff | Progesterone 400mg pessaries | £12.96 | 15 pessary | 1 Oct 2026 |
| NHS Drug Tariff | Progesterone 8% vaginal gel 1.125g applicators | £30.83 | 15 unit dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 15 Jul 2026 ENDOMETRIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 12 Feb 2026 BIJUVA — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 12 Feb 2026 PROMETRIUM — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions - EMA PRAC 12 May 2023 PRAC signal: Meningioma
Action for MAH: update of the product information: No - EMA PRAC 13 Jan 2023 PRAC signal: Meningioma
Action for MAH: update of the product information: No - US FDA 21 Aug 2018 PROGESTERONE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions
Combinations containing Progesterone
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.